{"id":"steroids-therapy","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Weight gain"},{"rate":"10-20%","effect":"Insomnia"},{"rate":"5-15%","effect":"Mood changes"},{"rate":"5-10%","effect":"Increased blood pressure"},{"rate":"5-10%","effect":"Osteoporosis"},{"rate":"5-10%","effect":"Glucose intolerance"}]},"_chembl":{"chemblId":"CHEMBL4298181","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Corticosteroids work by binding to glucocorticoid receptors, which then translocate to the nucleus and regulate the expression of genes involved in inflammation and immune response. This leads to a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines.","oneSentence":"Steroids therapy involves the use of corticosteroids to suppress the immune system and reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:27.988Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Multiple sclerosis"},{"name":"Asthma"},{"name":"Allergic reactions"}]},"trialDetails":[{"nctId":"NCT03856229","phase":"NA","title":"Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS","status":"ENROLLING_BY_INVITATION","sponsor":"Centro de Investigación en. Enfermedades Infecciosas, Mexico","startDate":"2019-03-04","conditions":"Pneumocystis, HIV/AIDS, Steroid","enrollment":196},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":"Lymphoma","enrollment":129},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":36},{"nctId":"NCT07496060","phase":"PHASE4","title":"Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-08-10","conditions":"Anterior Chamber Granulomatous Uveitis","enrollment":66},{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT05462730","phase":"PHASE2","title":"Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Thomas Engstrom","startDate":"2022-11-14","conditions":"ST Elevation Myocardial Infarction, Inflammatory Response, Myocardial Reperfusion Injury","enrollment":530},{"nctId":"NCT07495007","phase":"PHASE1","title":"An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection","status":"COMPLETED","sponsor":"Zi Diligence Biocenter","startDate":"2025-11-10","conditions":"Bioequivalance, Post-menopause","enrollment":26},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT06635447","phase":"PHASE3","title":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-26","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT04886960","phase":"PHASE1, PHASE2","title":"pAF for the Treatment of Osteoarthritis","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-07-08","conditions":"Osteo Arthritis Knee","enrollment":60},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT05896839","phase":"PHASE1, PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":16},{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Advanced Solid Malignancies","enrollment":41},{"nctId":"NCT07495566","phase":"","title":"Inflammatory Markers in Lumbar Radicular Pain Treated With PRF and TFESI","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2025-12-30","conditions":"Inflammatory Response, Radiculopathy, Radiculopathy Lumbar","enrollment":264},{"nctId":"NCT07495501","phase":"","title":"Patient Satisfaction During Lomber Transforaminal Epidural Steroid Injection: The Role of Sedation, Anxiety, and Pain","status":"NOT_YET_RECRUITING","sponsor":"Mersin University","startDate":"2026-04-01","conditions":"Lumbar Disc Disease, Radiculopathy Lumbar, Radicular Pain","enrollment":120},{"nctId":"NCT00428142","phase":"PHASE2","title":"Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-05-01","conditions":"Lymphoma","enrollment":95},{"nctId":"NCT05538897","phase":"PHASE1, PHASE2","title":"Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-31","conditions":"FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma","enrollment":96},{"nctId":"NCT06783621","phase":"PHASE4","title":"A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-01-16","conditions":"Facial Contouring","enrollment":130},{"nctId":"NCT07489521","phase":"PHASE4","title":"Arthrosemid vs. Steroid for the Management Knee Osteoarthritis","status":"RECRUITING","sponsor":"Cappagh National Orthopaedic Hospital","startDate":"2026-03","conditions":"Osteo Arthritis Knee, Osteoarthritis, Intraarticular Injection","enrollment":200},{"nctId":"NCT07497776","phase":"PHASE4","title":"Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome","status":"COMPLETED","sponsor":"National Institute of Kidney Disease and Urology (NIKDU)","startDate":"2024-01-27","conditions":"Dyslipidaemia","enrollment":100},{"nctId":"NCT05893069","phase":"PHASE4","title":"Oxandrolone Multiligament Knee","status":"SUSPENDED","sponsor":"George F. Hatch","startDate":"2023-07-01","conditions":"Ligament Tear Knee","enrollment":60},{"nctId":"NCT01846390","phase":"PHASE1","title":"Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2013-10-01","conditions":"Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":21},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT04751175","phase":"PHASE4","title":"Management of Pain in Lumbar Arthrodesis","status":"COMPLETED","sponsor":"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","startDate":"2013-07-04","conditions":"Pain, Postoperative","enrollment":128},{"nctId":"NCT04633252","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-23","conditions":"Cancer Of Prostate, Prostate Neoplasms","enrollment":86},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT06649812","phase":"PHASE2","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-07","conditions":"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":120},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT06726148","phase":"PHASE1, PHASE2","title":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-03","conditions":"Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors","enrollment":280},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT03436654","phase":"PHASE2","title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-21","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":"Recurrent AL Amyloidosis, Refractory AL Amyloidosis","enrollment":24},{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":"Breast Cancer","enrollment":193},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT07498478","phase":"PHASE2","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","status":"RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-03-17","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT04886999","phase":"PHASE3","title":"Study in Adult Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-24","conditions":"Asthma","enrollment":78},{"nctId":"NCT05601440","phase":"PHASE2","title":"Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2023-06-13","conditions":"Breast Cancer","enrollment":484},{"nctId":"NCT02143414","phase":"PHASE2","title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-30","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":53},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT07496294","phase":"NA","title":"Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2026-04","conditions":"Menopausal Women, Menopausal Symptom Relief, Hormone Therapy","enrollment":200},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT06998407","phase":"PHASE1, PHASE2","title":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-08-20","conditions":"HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":380},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT04835129","phase":"PHASE2","title":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-01-10","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT07409779","phase":"NA","title":"Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis","status":"NOT_YET_RECRUITING","sponsor":"Faculty of Medicine of Tunis","startDate":"2026-04-01","conditions":"Adhesive Capsulitis of the Shoulder","enrollment":50},{"nctId":"NCT05139316","phase":"PHASE3","title":"A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-11-08","conditions":"Glycogen Storage Disease Type IA","enrollment":49},{"nctId":"NCT07476209","phase":"NA","title":"Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2026-04-01","conditions":"Radiation Induced Xerostomia","enrollment":42},{"nctId":"NCT06610968","phase":"NA","title":"Acute Vitamin D Supplementation on Testosterone in Females","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2025-07-01","conditions":"Female Hormone Profile","enrollment":20},{"nctId":"NCT03431350","phase":"PHASE2","title":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-02","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":136},{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT05845125","phase":"PHASE4","title":"Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone","status":"TERMINATED","sponsor":"Claire Bourgeois","startDate":"2023-05-21","conditions":"Shoulder Pain","enrollment":50},{"nctId":"NCT07270549","phase":"PHASE1, PHASE2","title":"Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome","status":"RECRUITING","sponsor":"CTNNB1 Foundation","startDate":"2025-11-01","conditions":"CTNNB1 Neurodevelopmental Syndrome","enrollment":12},{"nctId":"NCT06932562","phase":"PHASE3","title":"A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2025-12-23","conditions":"Multiple Myeloma","enrollment":1000},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT04760717","phase":"PHASE2","title":"Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-03-19","conditions":"Intracerebral Hemorrhage, Ischemic Stroke, Spironolactone","enrollment":160},{"nctId":"NCT07452198","phase":"PHASE3","title":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2026-03-09","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT06578728","phase":"PHASE4","title":"Local Methotrexate Injections for the Treatment of Nail Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-09-10","conditions":"Nail Psoriasis","enrollment":1},{"nctId":"NCT07492888","phase":"PHASE2","title":"Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis","enrollment":20},{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT04933539","phase":"PHASE2","title":"Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-31","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT05119413","phase":"PHASE2","title":"Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2021-11-30","conditions":"Melanosis","enrollment":40},{"nctId":"NCT01712620","phase":"PHASE2","title":"Spironolactone for Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2014-01-10","conditions":"Pulmonary Arterial Hypertension","enrollment":70},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT04149210","phase":"PHASE3","title":"FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-08-19","conditions":"Trachomatous Trichiasis (TT), Eye Diseases, Eyelid Diseases","enrollment":2410},{"nctId":"NCT07489911","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)","status":"RECRUITING","sponsor":"Chiesi Slovenija, d.o.o.","startDate":"2024-11-04","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":200},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT07228026","phase":"","title":"Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects","status":"RECRUITING","sponsor":"Biometry Inc","startDate":"2025-09-17","conditions":"Asthma","enrollment":160},{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT06457919","phase":"PHASE1, PHASE2","title":"A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-06-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT02870738","phase":"PHASE2","title":"Bladder Directed vs. Pelvic Floor Therapy in IC/BPS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corewell Health East","startDate":"2017-04-21","conditions":"Cystitis, Interstitial, Painful Bladder Syndrome","enrollment":128},{"nctId":"NCT04563923","phase":"PHASE2","title":"Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2020-10-10","conditions":"Bullous Pemphigoid","enrollment":15},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":"Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":392},{"nctId":"NCT06235567","phase":"PHASE1, PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT07488728","phase":"NA","title":"Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2025-10-01","conditions":"EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir","enrollment":80},{"nctId":"NCT07479979","phase":"PHASE1, PHASE2","title":"Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Natalie Callander","startDate":"2026-07","conditions":"Relapse Multiple Myeloma, Refractory Multiple Myeloma","enrollment":62},{"nctId":"NCT03926299","phase":"NA","title":"Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Prof. Dr. Volker Viereck","startDate":"2019-07-15","conditions":"Chronic Skin Disease, Vulvar Lichen Sclerosus","enrollment":66},{"nctId":"NCT06851754","phase":"PHASE3","title":"Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2025-07-17","conditions":"Premature Ovarian Insufficiency","enrollment":185},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":313,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Steroids therapy","genericName":"Steroids therapy","companyName":"Beijing Tiantan Hospital","companyId":"beijing-tiantan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Steroids therapy involves the use of corticosteroids to suppress the immune system and reduce inflammation. Used for Rheumatoid arthritis, Multiple sclerosis, Asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}